Safety, pharmacokinetics and acceptability of PC-1005 for vaginal use
This Phase 1 clinical trial will evaluate MIV-150, a third generation non-nucleoside reverse transcriptase inhibitor, co-formulated with a potentially potent agent, zinc acetate for the prevention of HIV infection in women. This is the first in-human of PC-1005 (MIV-150/zinc acetate in a carrageenan gel), the first study in which females will be exposed to MIV-150, the first time MIV-150 will be administered topically, and the first time MIV-150 will be administered intravaginally.
Population Council (2015). Safety, pharmacokinetics and acceptability of PC-1005 for vaginal use (Clinicaltrials.gov Identifier NCT02033109). Retrieved from https://clinicaltrials.gov/ct2/show/NCT02033109
ClinicalTrials.gov Identifier: NCT02033109